Comparative Pharmacology
Head-to-head clinical analysis: COPEGUS versus FOSCAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COPEGUS versus FOSCAVIR.
COPEGUS vs FOSCAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ribavirin is a nucleoside analogue that inhibits viral RNA synthesis by interfering with RNA capping and polymerase activity, and may also modulate immune responses.
Foscarnet is a pyrophosphate analog that selectively inhibits viral DNA polymerase and reverse transcriptase by binding to the pyrophosphate binding site, preventing the cleavage of pyrophosphate from deoxynucleotide triphosphates, thereby inhibiting viral DNA synthesis. It does not require activation by viral thymidine kinase, making it active against acyclovir-resistant HSV and VZV, and ganciclovir-resistant CMV.
800 mg orally twice daily to 1200 mg orally twice daily based on body weight (≤75 kg: 800 mg; >75 kg: 1200 mg), in combination with ribavirin, for 24 to 48 weeks depending on genotype.
Induction: 60 mg/kg IV every 8 hours for 2-3 weeks, then maintenance: 90-120 mg/kg IV once daily. Administer as a 2-hour infusion via central line.
None Documented
None Documented
Terminal elimination half-life is approximately 120-170 hours following multiple doses, supporting once-daily dosing with prolonged viral suppression.
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function; can extend to 48-120 hours in severe renal impairment (CrCl <20 mL/min), requiring dose adjustment and therapeutic drug monitoring.
Ribavirin is primarily eliminated renally as unchanged drug (61%) and metabolites (30%); biliary/fecal excretion accounts for ~9%.
Primarily renal excretion (>80% as unchanged drug) via glomerular filtration and tubular secretion; minimal biliary/fecal elimination (<5%).
Category C
Category C
Antiviral
Antiviral